News
The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic ...
10h
Pharmaceutical Technology on MSNNovartis’ ribociclib approved in Canada for early breast cancerHealth Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the adjuvant treatment of adults with stage II-III early breast ...
EULAR now recommends moving directly to biologic or targeted synthetic disease-modifying antirheumatic drugs if the initial ...
After its $1 billion acquisition by Novartis, Mariana Oncology is expanding its Massachusetts real estate. Biotech's Future - ...
LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- The market for Paroxysmal Nocturnal Hemoglobinuria PNH and Atypical Hemolytic Uremic Syndrome aHUS has seen remarkable ...
Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...
Sanofi paid a more than 300% premium on its acquisition of Vigil Neuroscience, suggesting a fierce battle to seal the deal.
Novartis AG has disclosed huntingtin (HTT; HD) (mutant) splicing modulators reported to be useful for the treatment of familial dysautonomia, Huntington’s disease and spinal muscular atrophy.
Trump's NIH cuts are gutting university labs that fuel Big Pharma's drug pipeline and pushing U.S. biotech jobs, research, ...
7d
Zacks Investment Research on MSNNovartis AG (NVS) Hit a 52 Week High, Can the Run Continue?Shares of Novartis (NVS) have been strong performers lately, with the stock up 11.4% over the past month. The stock hit a new 52-week high of $120.92 in the previous session. Novartis has gained 24.1% ...
In its continued bid to waylay the launch of MSN Pharmaceuticals’ proposed Entresto generic, Novartis has told a federal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results